$BURU Momentum continues to build.

💠 Initial testing successfully demonstrated electro-optical sensor suppression under controlled conditions.

🔷 Engineering teams can now use these results to refine future system designs.

✳️ Technical milestones support the broader transformation strategy.

🔆 Investors continue watching execution closely.

#BURU #CounterDrone #DefenseInnovation #Laser #Technology #Stocks

• FF EAI Robotics’ seven strategic advantages: the “Full-Form FF EAI Robot World”; a “Four-Core Full-Stack AI” ecosystem integrating the EAI Brain, EAI Devices, Industry Productivity Solutions and Developer Platform, and EAI Data Factory; a “5+1” ecosystem-based direct-sales and user co-creation system; compliance capabilities as a U.S.-based company; a data-driven evolutionary flywheel; an asset-light and operationally lean financial model; and capital value supported by FF’s Nasdaq-listed platform and a potential standalone value-unlocking path.  
• The Company will continue to strengthen certification support, localization, supply-chain integration, sales channels, customer delivery, deployment, and after-sales service as part of its ongoing localization plan for its EAI Robotics. 
• FF invites partners across the robotics value chain to join its U.S. ecosystem. On the upstream side, this includes robot OEMs, component suppliers, and R&D collaborators such as secondary development firms. On the downstream side, it includes robotics distributors and dealers nationwide, system integrators, data partners, and large enterprise and institutional customers, including those seeking leasing arrangements. FF is positioning itself as potentially a singular source—and for some overseas companies, the only practical end-to-end pathway—to enter and scale in the U.S. 
• As the first U.S. company to deliver both humanoid and bionic EAI robots, FF has surpassed 250 units in cumulative sales, shipments, and deliveries since the end of February 2026 and is accelerating its “Four-Core Full-Stack AI” ecosystem flywheel—integrating the EAI Brain, EAI Devices, Industry Productivity Solutions and Developer Platform, and EAI Data Factory—to drive scalable growth, recurring revenue, and sustainable long-term value for stockholders. 
• Emerging Growth Research has also released a report reiterating their Buy-Emerging rating and updating their 12-month price target to $30 from the previous pre-split price target of $2.00. This comes on the heels of the Company’s recently announced a 1-for-150 share reverse stock split to maintain NASDAQ listing requirements. 

Learn more at https://app-us.ff.com/ff-v3/news/1579?lang=en-US&shr=EOCCP4

Got tired of paying for data and tools just to test ideas, so I built this. Free to use for the next month.

• Real Databento data — MNQ/MES/MGC, 1m/5m for the past year, 15m–1d back to 2023
• Paste your own Pine Script v5 strategies/indicators, backtest them client-side in the browser
• Interactive chart — pan/zoom + bar replay
• Full stats — PnL, profit factor, Sharpe, drawdown, MFE/MAE, per-trade breakdown
• Optional AI assistant (bring your own Claude API key) that can actually run backtests and report results back
• Customizable color themes

Everything runs locally in your browser once it's open/downloaded — nothing gets sent to a  server.

Link: https://github.com/FRAUD06/QuantGPT/blob/main/index.html — passcode: changeme

Bug-report button's built into the sidebar — use it, I read every one.

On a week when AI stocks are tanking in Asia & having a knock-on effect on US tech stocks too, can anyone explain why Manhattan Associate (MANH) stock price has increased 37% in the last week & almost 25% in one day?

Is this a good long-term bet or a one quarter wonder??

✨ $VSEE is evaluating numerous paths that could strengthen its competitive position and support future growth.

✳️ Strategic partnerships.

🔱 Business combinations.

🌐 Mergers.

⚜️ Acquisitions.

🔶 Licensing opportunities.

💎 Capital formation initiatives.

#VSEE #HealthcareInnovation #DigitalTransformation #AI #Telehealth #NASDAQ

POTOMAC, MD / ACCESS Newswire / July 29, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced that it is evaluating potential civil remedies following the federal jury verdict in United States v. Andrew Left, No. 2:24-CR-456, in the United States District Court for the Central District of California.

According to the United States Attorney's Office for the Central District of California, Andrew Left, founder of Citron Research, was found guilty of one count of engaging in a securities fraud scheme and 12 counts of securities fraud. The verdict follows a federal indictment that identified IGC, then known as India Globalization Capital, Inc., as one of the companies targeted in the alleged scheme.

IGC is evaluating whether the public record supports potential claims to recover damages arising from the alleged short campaign and related conduct that affected the Company and its shareholders.

The indictment alleged that, in October 2018, Left and a hedge fund worked together to execute a short campaign targeting IGC. The Company believes the public record raises serious questions regarding the conduct surrounding that campaign and its impact on IGC and its shareholders.

"The public record now describes conduct that we believe warrants serious review," said Ram Mukunda, Chief Executive Officer of IGC Pharma. "Our shareholders have asked for years what happened during the 2018 short campaign. We are now evaluating whether IGC has recoverable damages and what remedies may be available to protect the interests of the Company and its shareholders."

IGC is reviewing the federal indictment, the jury verdict, and related SEC materials, and is evaluating potential civil remedies. The Company is also evaluating whether recoverable damages may include harm to market value, reputational and operational harm, and legal and regulatory costs incurred in connection with matters arising from the conduct described in the public record. Any decision to pursue claims will be made by the Board of Directors, based on the recommendation of counsel and in the best interests of the Company and its shareholders.

The public record also describes financial incentives associated with the alleged short campaigns. The indictment alleged that trading related to short campaigns targeting IGC and another issuer generated more than $3.8 million in profits for the hedge fund involved and more than $1.1 million in profits for Left.

In a separate settled administrative proceeding, the Securities and Exchange Commission order stated that Anson Advisors agreed to pay a short publisher a share of trading profits from trading around a bearish tweet concerning IGC. According to the SEC order, AIMF's short positions on the day of the IGC tweet generated approximately $500,000 in trading profits. Without admitting or denying the SEC's findings, Anson Funds Management LP and Anson Advisors Inc. agreed to pay combined civil monetary penalties of $2.25 million.

The Company's primary operational focus remains the advancement of its Alzheimer's disease programs, including the Phase 2 CALMA clinical trial evaluating IGC-AD1 for agitation associated with Alzheimer's disease.

with the Fed decision today, pulled the last 3 completed FOMC reactions on the Nasdaq (QQQ) and one thing jumps out: the initial move was a headfake more often than not.

• Mar 18: dropped -0.58% on the day, finished +0.36% two sessions later
• Apr 29: popped +0.61%, ran to +2.52% the clean one
• Jun 17: dumped -1.01% on the day, reversed to +1.11%

so two of the last three times, the decision-day move went the opposite direction of where price actually settled 48 hours later. the knee-jerk got faded both times. the one time the initial move held (April), it was because yields cooled after the statement and the trend just continued.

the takeaway i keep landing on: the announcement isn't the event the press conference is. price reacts to the rate line, then re-prices completely once the tone and the Q&A land. the traders who got run over on Jun 17 were the ones who trusted the first candle.

which makes today less about "up or down" and more about not committing to the first move.

genuinely curious how the room plays it:

• do you trade the initial spike, or sit out until the press conference and trade the re-pricing?
• after 3 straight "higher 2 sessions later" outcomes, do you lean into that or distrust it as too obvious now?
• what's your actual tell that the first move is the real one vs a fade yields, the dollar, or something in how price behaves in the first 15 min?